88 results about "Neurological injury" patented technology

The present invention provides a method of inhibiting oxidative-stress induced cell death in a cell comprising contacting the cell with a composition comprising a benzoquinoid ansamycin. The present invention further provides a method of reducing neurological injury resulting from cardiac arrest or stroke comprising administering to a patient a composition comprising a benzoquinoid ansamycin.

Methods and devices for providing therapeutic electromagnetic field treatment to a subject having a cognitive or neurological condition or injury. Treatment devices can include headwear incorporating electromagnetic treatment delivery devices providing electromagnetic treatment to a user's head area. Such devices include protective headwear such as helmets with electromagnetic delivery devices. Additionally, embodiments of the invention provide for wearable and adjustable electromagnetic treatment devices that can be used to provide electromagnetic treatment to multiple areas of the user's head. Embodiments of the invention provide for sequential electromagnetic treatment with a single or a plurality of treatment applicators which target a single or multiple cerebral regions as determined by imaging, non-imaging and physiological monitoring before, during and after electromagnetic treatment.

Methods of enabling locomotor control, postural control, voluntary control of body movements (e.g., in non-weight bearing conditions), and / or autonomic functions in a human subject having spinal cord injury, brain injury, or neurological neuromotor disease. In certain embodiments, the methods involve stimulating the spinal cord of the subject using an epidurally placed electrode array, subjecting the subject to physical training thereby generating proprioceptive and / or supraspinal signals, and optionally administering pharmacological agents to the subject. The combination of stimulation, physical training, and optional pharmacological agents modulate in real time electrophysiological properties of spinal circuits in the subject so they are activated by supraspinal information and / or proprioceptive information derived from the region of the subject where locomotor activity is to be facilitated.

Methods are described comprising: administering to a mammal with a paralysis an electrical enabling motor control stimulation to at a sub-threshold location, wherein the electrical enabling motor control stimulation provides spontaneous voluntary movement of at least one body part.

Described herein are methods of treating neurological injury and conditions, in particular neurodegenerative conditions. These treatment methods can include the steps of generating a pulsed electromagnetic field from a pulsed electromagnetic field source and applying the pulsed electromagnetic field in proximity to a target region.

Processes and materials are provided for the detection, diagnosis, or determination of the severity of a neurological injury or condition, including traumatic brain injury, multiple-organ injury, stroke, Alzeimer's disease, Pakinson disease and Chronic Traumatic Encephalopathy (CTE). The processes and materials include biomarkers detected or measured in a biological sample such as whole blood, serum, plasma, or CSF. Such biomarkers include Tau and GFAP proteins, their proteolytic breakdown products, brain specific or enriched micro-RNA, and brain specific or enriched protein directed autoantibodies. The processes and materials are operable to detect the presence of absence of acute, subacute or chronic brain injuries and predict outcome for the brain injury.

This disclosure provides non-invasive methods to induce motor control in a mammal subject to spinal cord or other neurological injuries. In certain embodiments the method involves administering transcutaneous electrical spinal cord stimulation (tSCS) to the mammal at a frequency and intensity that induces the desired locomotor activity.

Treatment of neurological injury through motor relearning. A game-based sensorimotor rehabilitator that enables individuals to interact with the functional objects using the appropriate amount of force, tilt, finger movement, and muscle activity to regain lost skill due to injury.

Methods of enabling locomotor control, postural control, voluntary control of body movements (e.g., in non-weight bearing conditions), and / or autonomic functions in a human subject having spinal cord injury, brain injury, or neurological neuromotor disease. In certain embodiments, the methods involve stimulating the spinal cord of the subject using an epidurally placed electrode array, subjecting the subject to physical training thereby generating proprioceptive and / or supraspinal signals, and optionally administering pharmacological agents to the subject. The combination of stimulation, physical training, and optional pharmacological agents modulate in real time electrophysiological properties of spinal circuits in the subject so they are activated by supraspinal information and / or proprioceptive information derived from the region of the subject where locomotor activity is to be facilitated.

An electro diagnostic functional assessment unit (EFA-2) that diagnoses age of and treats soft tissue injuries. The EFA-2 utilizes sensor(s) including EMG, Range of Motion, FCE, pinch and grip, and allows for monitoring of muscles and muscle groups to ascertain compliance, pain and function. The EFA-2 also monitors disc pathology and determines whether a person requires surgery or conservative care and, the age of the disc. Additionally, the EFA-2 monitors EEK activity and NCV, as well as invasive EMG that monitors nerve damage. Previously, with NCV the temperature and the position of electrodes would effect readings and produce false positive or false negative readings. The EFA-2 eliminates these problems by incorporating temperature sensor(s) and electrode placement sensor(s). The EFA-2 also provides direct treatment by means of ultrasound and electrical stimulation. Thus, the EFA-2 allows diagnosis any treatment by means of a single unit.

The present invention provides systems and methods for detection and diagnosis of concussion and / or acute neurologic injury comprising a portable headwear-based electrode array and computerized control system to automatically and accurately detect cortical spreading depression and acute neurological injury-based peri-infarct depolarization (CSD / PID). The portable headwear-based electrode system is applied to a patient or athlete, and is capable of performing an assessment automatically and with minimal user input. The user display indicates the presence of CSD / PID, gauges its severity and location, and stores the information for future use by medical professionals. The systems and methods of the invention use an instrumented DC-coupled electrode / amplifier array which performs real-time data analysis using unique algorithms to produce a voltage intensity-map revealing the temporally propagating wave depressed voltage across the scalp that originates from a CSD / PID on the brain surface.

Embodiments of the invention include methods of treating neurological injury and conditions, in particular, traumatic brain injury and physiological responses arising from injury or conditions. These treatment methods can include the steps of generating a pulsed electromagnetic field from a pulsed electromagnetic field source and applying the pulsed electromagnetic field 1 in proximity to a target region affected by the neurological injury or condition to reduce a physiological response to the neurological injury or condition.

An in vitro diagnostic (IVD) device is used to detect the presence of and / or severity of neural injuries or neuronal disorders in a subject. The IVD device relies on an immunoassay which identifies biomarkers that are diagnostic of neural injury and / or neuronal disorders in a biological sample, such as whole blood, plasma, serum, and / or cerebrospinal fluid (CSF). An IVD device may measure one or more of several neural specific markers in a biological sample and output the results to a machine readable format, either to a display device or to a storage device internal or external to the IVD.

The present invention relates to ligands of the peripheral cannabinoid receptor CB2, especially (+)-α-pinene derivatives, and to pharmaceutical compositions thereof, which are useful for promoting, inducing and enhancing neurogenesis including neural cell regeneration. In particular, pharmaceutical compositions of the invention will be useful for preventing, alleviating or treating neurological injuries or damages to the CNS or the PNS associated with physical injury, ischemia, neurodegenerative disorders, certain medical procedures or medications, tumors, infections, metabolic or nutritional disorders, cognition or mood disorders, and various medical conditions associated with neural damage or destruction.

The present invention relates to methods of using zFGF5 compositions to proliferate chondrocytes and their progenitors, and to induce deposition of cartilage. zFGF5 compositions are disclosed for treating disorders associated with chondrocytes, such as cartilage injuries and defects. In addition, methods for treating neurological disorders, such as stroke, are disclosed, and methods for using zFGF5 compositions to stimulate growth of cells associated with neurological injury and disease are disclosed.

A folding wallet configured to fit the front pockets of trousers, thereby encouraging such use to avoid neurological injury caused by carrying a wallet in the rear pockets of trousers.

The present invention relates to pharmaceutically acceptable compounds, including certain substituted indolinyl and derivatives thereof, 1,2,3,4-tetrahydroquinolinyl and derivatives thereof, 1,2,3,4-tetrahydroisoquinolinyl, benz[cd]indolinyl and 5,6-dihydrophenanthridinyl compounds, and methods of treatment and pharmaceutical compositions that utilize or comprise one or more such compounds. Compounds of the invention are particularly useful for the treatment or prophylaxis of neurological injury and neurodegenerative disorders.

This invention relates to novel α-conotoxin-like peptides comprising the following sequence of amino acids: Xaa1CCSXaa2Xaa3Xaa4CXaa5Xaa6Xaa7Xaa8Xaa9Xaa10Xaa11C—NH2 in which Xaa1 is G or D; Xaa3 is proline, hydroxyproline or glutamine; each of Xaa2 to Xaa8 and Xaa11 is independently any amino acid; Xaa9 is proline, hydroxyproline or glutamine; Xaa10 is aspartate, glutamate or γ-carboxyglutamate; Xaa11 is optionally absent; and the C-terminus is optionally amidated, with the proviso that the peptide is not α-conotoxin Ep1 or α-conotoxin Im1. The peptides are useful in the treatment or prevention of pain, in recovery from nerve injury, and in the treatment of painful neurological conditions such as stroke.

The invention relates to tPA mutant devoid of protease activity and uses thereof in compositions and methods for the treatment and prevention of pathologic conditions involving neurological injury or an ischemic disease or condition. More specifically, the invention relates to a Ser481 to Ala mutant of tPA and to compositions and combinations thereof for the treatment of stroke, acute brain injury and neurodegenerative disorders. The invention further provides methods and kits for the treatment of said disorders.

A system and methods for neurophysiological assessements during surgical procedures are disclosed. The health and status of the lower motor neural pathway is established in tissues having neural structures which if contacted or impinged may result in neural impairment for the patient. A computer-implemented method monitors the health of the lower motor neural pathway before, during spinal surgery. The method includes delivering a first transcutaneous, trans-abdominal stimulation signal to a spinal nerve root superior to a surgical target site; and determining neuromuscular response data set based on transmission on the stimulation signal to a muscle located inferior to the surgical target site.

A neurological monitoring method and system that allows a user to monitor a neurological organ while recovering from a neurological injury. The neurological monitoring method allows the user to recover from the injury, and an invited follower to map the neurological organ and study the neurological organ from a display device. The method includes sensing the organ with a sensor, such as EEG electrodes. A signal generated by the neurological organ is then recorded by the sensor and transmitted to data storage, including a cloud. The signal can be reconfigured and retransmitted to a display device. The signal includes Hertz and real time frequencies. The signal includes a signal parameter with a high range and a low range. An alert actuates when the signal exceeds the parameter. The signal is monitored by the user and invited followers for better understanding the condition of the neurological organ.

Neuro-enhancing agents, compositions and methods are disclosed herein. Preferred neuro-enhancing agents of the present invention include progesterone and metabolites of progesterone, such as 3α-hydroxy-5α-pregnan-20-one (THP). These agents yield neuro-enhancing effects on neural cells that include neural progenitor and / or stem cells, whereby the agents stimulate mitosis of neural progenitor cells, stimulate neurite growth and organization, protect against neural loss, or one or more of these neural processes. Thus, the neuro-enhancing agents, compositions and methods disclosed herein are useful to reverse or prevent neurological disease or defects associated with neural loss or degeneration, such as Alzheimer's disease, neurological injuries, including injuries resulting from radiation therapy, and age-related neurological decline, including impairments in memory and learning.

A system (10) and method for detecting and analyzing neurological damage in an injured subject are provided using electrical nerve conduction analyses supported by a computing device (12). An appropriate neurologically protective pharmaceutical for that injury type and circumstances based on the result of said analyses is suggested.

The invention discloses a dental pulp stem cell exosome preparation as well as a preparation method and application thereof, and relates to the technical field of biology. Dental pulp stem cells can express neuronal cell surface markers, can be differentiated to nerve cells and promote the proliferation of the nerve cells, so that the dental pulp stem cells can be used for preparing cell preparations for repairing nerve injuries such as traumatic brain injuries (TBI). The dental pulp stem cells are used for replacing traditional embryonic stem cells, neural stem cells or bone marrow stem cellsto be used for treating the nerve injuries, and have the advantages of being rich in source, simple and convenient to obtain, low in immunogenicity and capable of avoiding ethical problems. Dental pulp stem cell exosomes can accurately target recipient cells and are used for preparing nerve repair preparations for the injuries such as the TBI, and then treatment of the nerve injuries such as theTBI by the exosomes is achieved. The dental pulp stem cell exosomes can also be used for preparing neuroinflammation inhibitors.